

# Transient Receptor Potential Vanilloid 1 (TRPV1) in Haematological Malignancies

**Sofia Atif (Moh'dAli) Omari**

B.Sc., M.Sc. (Medical Laboratory Sciences)

Jordan University of Science and Technology

A thesis submitted in fulfilment of the requirements for the

Degree of Doctor of Philosophy

School of Human Life Sciences

University of Tasmania

May 2014

## **Dedication**

*To my parents, husband Asal, son Awsam and my newborn Karam.*

*With all my love....*

### **Declaration of Originality**

This thesis contains no material which has been accepted for a degree or diploma by the University or any other institution, except by way of background information and duly acknowledged in the thesis, and to the best of my knowledge and belief no material previously published or written by another person except where due acknowledgement is made in the text of the thesis, nor does the thesis contain any material that infringes copyright.

Full Name **Sofia Atif (Moh'dAli) Omari**

Signed .....

Date .....

### **Authority of Access**

This thesis is not to be made available for loan or copying for two years following the date this statement was signed. Following that time the thesis may be made available for loan and limited copying and communication in accordance with the Copyright Act 1968.

Full Name **Sofia Atif (Moh'dAli) Omari**

Signed .....

Date .....

### **Statement of Ethical Conduct**

The research associated with this thesis abides by the international and Australian codes on human and animal experimentation, the guidelines by the Australian Government's Office of the Gene Technology Regulator and the rulings of the Safety, Ethics and Institutional Biosafety Committees of the University. This study was approved by the Human Research Ethics Committee Network, Tasmania (Approval No. H0011050).

Full Name **Sofia Atif (Moh'dAli) Omari**

Signed .....

Date .....

## **Acknowledgments**

I would like to express my sincere gratitude and appreciation to everyone who has been involved in the work of this thesis, with special thanks to the following

Dr. Murray Adams and Prof. Dominic Geraghty, my supervisors, not only for being the initiators and facilitators of this research, but also for their invaluable guidance, flexibility, patience, support and ability to help me through the tough times. They always kept focussing on the optimistic side and encouraged me to get through any frustration. I can't say enough to thank you both! You maintained the smile on my face even when I wasn't in the mood.

Assoc. Prof. Alhossain Khalafallah, my research advisor, for the support and help he provided in recruiting patients, and for his enthusiasm and dedication to research, and to the in-need. I would also like to thank the participants involved in this study without whom, this research would not have been possible.

Dr. Dale Kunde for his technical support and troubleshooting, Dr. Anthony Cook for his invaluable advice, Prof. Peter McIntyre for his gift of TRPV1-transfected HEK293 cells and Dr. Rajaraman Eri for his support and RAW264.7 cells.

The Clifford Craig Medical Research Trust and University of Tasmania for generous financial support, and Australian government for the Australian Postgraduate Award.

My colleagues; Yvette Shegog for her invaluable support and guidance during the preliminary stage of flow cytometry method development, Emma Walker for her collaboration in adherent cell culture and protein assay, staff in the School of Human Life Sciences, especially Dr. Kiran Ahuja, and the technical staff, in particular Merrillyn Johnson, for providing laboratory assistance.

Many thanks to my postgraduate research colleagues, Dr. Safa Al-Maghrabi, Katharine Herbert, Waheeda Basheer and all in the postgraduate room, for the nice times we spent together and for your support.

Special thanks are given to Dr. Scott Ragg and his team at the Royal Hobart Hospital for sharing their knowledge and advice with regard to flow cytometry, Launceston General Hospital Pathology, and Holman Clinic for their helping hands and support.

My parents had to grudgingly learn to accept my separation from them and still gave me nothing but support, day after day, my love and gratitude for them can hardly be expressed in words. I would also like to thank my loved ones, my two sisters Dareen and Noor, my three brothers Mohammad, Yahya and Islam, who have supported me throughout the entire process, by keeping me harmonious and believing in me.

Next in the list is my beloved, wonderful 3 year old son Awsam, who I gave birth to during my PhD candidature. Thank you sweetheart for your unconditional love and support, and for dealing with my frustrations during this journey. And to my newborn Karam, the most wonderful surprise in my life, who decided to come to life early and before I submit this thesis. I love you baby, you are my little angel!

Finally, but most importantly, I would like to thank my soul-mate and husband Asal for his patience and understanding in all those times I had to put this project first. Without your presence in my life, encouragement and endless love and support, I would never be where I am or achieve any of this. With you, the dream come true, I will always be grateful.

# Table of Contents

Dedication .....	i
Declaration of Originality.....	ii
Authority of Access.....	ii
Statement of Ethical Conduct.....	ii
Acknowledgments .....	iii
Table of Contents .....	v
List of Figures .....	viii
List of Tables.....	x
List of Abbreviations.....	xi
Presentations at Conferences during PhD Candidature .....	xv
Abstract .....	1
<b>1. Chapter 1: Literature Review .....</b>	<b>5</b>
1.1 Introduction.....	6
1.2 Overview of TRP Channels .....	6
1.3 Transient Receptor Potential Vanilloid 1 (TRPV1) .....	11
1.3.1 Structure .....	11
1.3.2 Activation of TRPV1.....	12
1.3.3 Expression of TRPV1.....	14
1.4 TRPV1 and Pain .....	15
1.4.1 TRPV1 and nociceptive pain.....	16
1.4.2 Sensitisation and desensitisation of TRPV1 receptors .....	16
1.5 TRPV1 and Disease .....	20
1.5.1 Neuropathic Pain Syndromes .....	20
1.5.2 Neurogenic Inflammation.....	21
1.5.3 Systemic Diseases .....	21
1.5.4 Vanilloid-induced Apoptosis and Cancer.....	23
1.6 TRPV1 Expression and Function in Immune System Cells.....	25
1.6.1 Lymphocytes .....	25
1.6.2 Macrophages .....	27
1.6.3 Neutrophils .....	29
1.7 The TRPV1: Role in Haematological Malignancies.....	29
1.7.1 Leukaemic cell lines.....	31
1.7.2 Adult T-cell leukaemia .....	32
1.7.3 Multiple Myeloma.....	33
1.8 Project Aims .....	34
1.9 Hypotheses.....	34
<b>2. Chapter 2: Capsaicin-Induced Death of Human Haematological Malignant Cell Lines is Independent of TRPV1 Activation .....</b>	<b>36</b>
2.1 Abstract.....	37
2.2 Introduction.....	38

2.3	Materials and Methods.....	40
2.3.1	Materials.....	40
2.3.2	Methods.....	40
2.3.3	Cryopreservation.....	43
2.3.4	Cell metabolic activity assays.....	43
2.4	Results.....	45
2.5	Discussion.....	53
<b>3.</b>	<b>Chapter 3: Validation and Optimisation of a Western Blotting Method to Detect TRPV1 Protein in Human Peripheral Blood Mononuclear Cells and Malignant Haematological Cell Lines .....</b>	<b>59</b>
3.1	Abstract.....	60
3.2	Introduction.....	61
3.3	Materials and Methods.....	61
3.3.1	Materials.....	61
3.3.2	Cells.....	62
3.3.3	Antibodies.....	62
3.3.4	Ethical Approval.....	62
3.3.5	Cell Processing.....	64
3.3.6	Protein Assay.....	65
3.3.7	Blocking Solutions Optimisation.....	65
3.3.8	Protein Quantity Optimisation.....	66
3.3.9	Western Blotting (Optimised Protocol).....	66
3.4	Results.....	69
3.4.1	Optimisation of the Western Blotting Protocol.....	69
3.4.2	Detection of TRPV1 in Human PBMCs using the Optimised Method.....	77
3.5	Discussion.....	78
<b>4.</b>	<b>Chapter 4: Development and Optimisation of a Flow Cytometric Method for the Detection of TRPV1 Expression in Human Leukocytes .....</b>	<b>85</b>
4.1	Abstract.....	86
4.2	Introduction.....	87
4.3	Materials and Methods.....	88
4.3.1	Materials.....	88
4.3.2	Methods.....	89
4.4	Results.....	93
4.4.1	Flow Cytometry Optimisation setup.....	93
4.4.2	Fixation and Permeabilisation Optimisation.....	94
4.4.3	Assessment of the Primary Antibodies.....	95
4.4.4	Secondary Antibody Assessment.....	98
4.4.5	Detection of TRPV1 in Human Normal Leukocytes using the Optimised Method ...	101
4.5	Discussion.....	102
<b>5.</b>	<b>Chapter 5: TRPV1 Expression in Human Haematological Malignancy Cell Lines .....</b>	<b>109</b>
5.1	Abstract.....	110

5.2	Introduction.....	111
5.3	Materials and Methods.....	112
5.3.1	Cells and Cell Culture .....	112
5.3.2	Western Blotting and Flow Cytometry Experiments.....	113
5.3.3	Data Collection and Analysis .....	114
5.4	Results.....	114
5.4.1	TRPV1 Expression in Malignant Haematological Cell lines .....	114
5.4.2	TRPV1 Expression in Other Cell lines: A Control Study .....	117
5.5	Discussion.....	120
<b>6.</b>	<b>Chapter 6: TRPV1 Expression in Patients with Haematological Malignancies .....</b>	<b>127</b>
6.1	Abstract.....	128
6.2	Introduction.....	129
6.3	Materials and Methods.....	129
6.4	Results.....	130
6.4.1	General Characteristics of Patients and Controls .....	130
6.4.2	Detection of TRPV1 using Flow cytometry .....	131
6.4.3	TRPV1 Detection Using Western blotting .....	139
6.5	Discussion.....	141
<b>7.</b>	<b>Chapter 7: Conclusions and Future Studies.....</b>	<b>148</b>
	<b>Appendix I: Preliminary Flow Cytometry Optimisation Using BD FACScalibur™ .....</b>	<b>157</b>
	<b>Appendix II: Patients and Control Subjects Consent Forms .....</b>	<b>166</b>
	<b>Appendix III: Experiments Sheets and Protocols.....</b>	<b>175</b>
	<b>References .....</b>	<b>185</b>

## List of Figures

Figure 1-1: Topological model of TRPV1 .....	12
Figure 1-2: TRPV1 signal transduction .....	18
Figure 1-3: TRPV1 status. ....	20
Figure 2-1: Differential response of THP-1, U266B1 and U937 cells to CAP.....	45
Figure 2-2: Effect of CAP and the TRPV1 antagonist, SB452533, on the metabolic activity (resazurin reduction) of THP-1, U266B1 and U937 cells .....	47
Figure 2-3: Effect of SB452533, AM251 and AM630 on CAP-induced change in metabolic activity (resazurin reduction) in THP-1 cells .....	50
Figure 2-4: Effect of SB452533, AM251 and AM630 on CAP-induced metabolic activity (resazurin reduction) of U266B1 cells .....	51
Figure 2-5: Effect of SB452533, AM251 and AM630 on CAP-induced metabolic activity (resazurin reduction) of U937 cells.....	52
Figure 3-1: TRPV1 detection attempt using the Biotin-Streptavidin detection system in THP-1 cells .....	70
Figure 3-2: ECL detection method with secondary antibody dilution study, 1:5000 vs. 1:10000 of Santa Cruz Biotechnology in THP-1 cells.....	70
Figure 3-3: Protein quantity study (10, 20 and 30 µg) of THP-1 cell lysate to detect TRPV1 with Santa Cruz anti-TRPV1 using the ECL method .....	71
Figure 3-4: TRPV1 detection using Alomone Labs anti-TRPV1 antibody .....	72
Figure 3-5: Detecting TRPV1 using LifeSpan Biosciences antibody.....	73
Figure 3-6: Titration & blocking studies for LifeSpan Biosciences Anti-TRPV1... ..	74
Figure 3-7: Secondary antibody (Santa Cruz Biotechnology) titration study.....	75
Figure 3-8: Secondary antibody (Cell Signalling Technology) dilution Study. ....	76
Figure 3-9: TRPV1 detected in normal human PBMCs protein.....	77
Figure 4-1: Example of optimised Attune® Cytometer settings using AbC™ beads. ....	94
Figure 4-2: FSC and SSC electronic optimisation for fixed/ permeabilised cells using the Attune® Flow Cytometer .....	94
Figure 4-3: Isotype control overlapping with TRPV1 signal in human leukocyte. ...	95
Figure 4-4: Santa Cruz Biotechnology anti-TRPV1 blocking optimisation using flow cytometry.....	96
Figure 4-5: Comparison between two isotype controls vs. Santa Cruz Biotechnology anti-TRPV1 .....	97
Figure 4-6: Alomone Labs anti-TRPV1 signal .....	97
Figure 4-7: Blocking step optimisation for anti-TRPV1 (LifeSpan Biosciences, USA) signal .....	99
Figure 4-8: Dilution study of LifeSpan Biosciences anti-TRPV1 .....	99
Figure 4-9: Secondary antibody titration for FITC-goat anti rabbit (Santa Cruz Biotechnology) using the Attune® Cytometer .....	100
Figure 4-10: TRPV1 detection in normal human WBCs using the optimised protocol. ....	101

Figure 5-1: TRPV1 expression was detected in THP-1 cells using Western blotting and flow cytometry .....	115
Figure 5-2: TRPV1 expression was detected in U266B1 cells .....	115
Figure 5-3: TRPV1 expression was detected in U937 lymphoma cells .....	116
Figure 5-4: Relative expression of TRPV1 in three haematological malignant cell lines .....	116
Figure 5-5: TRPV1 expression in TRPV1-transfected HEK293 cells (tetracycline (tet) on/off) by flow cytometry .....	117
Figure 5-6: TRPV1 expression in TRPV1-transfected HEK293 cells (tetracycline off) by Western blotting. ....	118
Figure 5-7: TRPV1 expression in untransfected HEK293 cells by Western blotting. ....	118
Figure 5-8: TRPV1 expression in HEK293 cells was confirmed by flow cytometry. ....	118
Figure 5-9: TRPV1 was detected in RAW264.7 cells. ....	119
Figure 6-1: TRPV1 expression in patients with haematological malignancies. ....	132
Figure 6-2: TRPV1 expression for all patients with haematological malignancies vs. controls.....	133
Figure 6-3: TRPV1 expression in patients with B-NHL.....	133
Figure 6-4: TRPV1 expression in patients with MM.....	137
Figure 6-5: TRPV1 expression in patients with other blood cancers.....	138
Figure 6-6: TRPV1 MFI ratio between males and females .....	138
Figure 6-7: TRPV1 expression in PBMCs protein samples of patients with haematological malignancies using Western Blotting.. ....	139

## List of Tables

Table 1-1: Overview of TRP family subgroups .....	8
Table 1-2: Summary of studies investigating the role of TRPV1 in systemic diseases and conditions .....	22
Table 1-3: Some non-haematological cell lines that undergo vanilloid-induced cell death .....	24
Table 1-4: Summary of TRPV1-expression and function in malignant haematological cell lines .....	30
Table 2-1: Characteristics of the studied haematological malignant cell lines.....	41
Table 2-2: EC <sub>50</sub> /IC <sub>50</sub> for CAP-induced metabolic activity in THP-1, U266B1 and U937 cells .....	46
Table 3-1: Characteristics of the primary rabbit anti-TRPV1 and anti-GAPDH antibodies .....	63
Table 3-2: Characteristics of secondary antibodies used in Western blot .....	64
Table 3-3: Western blotting protocols tested to detect TRPV1 in human malignant cell lines and PBMCs .....	67
Table 3-4: Summary of some studies detecting TRPV1 by Western blot .....	80
Table 4-1: Characteristics of the isotype controls used in the study.....	89
Table 4-2: Mean-MFI values for different normal leukocytes subpopulations .....	102
Table 4-3: Some published studies on TRPV1 expression detected by flow cytometry .....	103
Table 5-1: Comparison of TRPV1 Mean-MFI in THP-1, U266B1 and U937 cell lines and normal leukocytes.....	116
Table 5-2: TRPV1 MFI in some cell lines compared to normal leukocytes from healthy control.....	119
Table 6-1: General characteristics of patients with haematological malignancies ..	131
Table 6-2: Characteristics of B-NHL patients compared to control subjects used for analysis of TRPV1 expression by flow cytometry.....	134
Table 6-3: Characteristics of MM patients compared to control group subjects used for analysis of TRPV1 expression by flow cytometry .....	135
Table 6-4: Other haematological malignant cancers patients compared to control subjects used for analysis of TRPV1 expression by flow cytometry.....	136
Table 6-5: Patients with detected TRPV1 bands on Western Blotting .....	140
Table 6-6: Features of some drugs used to treat haematological malignancies.....	146

## List of Abbreviations

A-425619	1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)urea
A-778317	1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea
AA	Arachidonic acid
ACA	N-(p-amylcinnamoyl)anthranilic acid
ADP	Adenosine diphosphate
AEA	N-arachidonoylethanolamine (anandamide)
ALL	Acute lymphocytic leukaemia
AMG628	(R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide
AML	Acute Monocytic Leukaemia
AMP	Adenosine monophosphate
AMPK	AMP-activated protein kinase
AP-1	Activator protein-1
ATL	Adult T-cell leukaemia
ATP	Adenosine triphosphate
Bax	Bcl-2-associated X protein
Bcl-2	B-cell lymphoma 2
Bcl-xL	B-cell lymphoma-extra large
BCTC	N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide.
BDNF	Brain-derived neurotrophic factor
bFGF	Basic fibroblast growth factor
BTP2	4-methy-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide
C- terminus	Carboxy terminus
CaM	Calmodulin
CaMKII	Ca <sup>2+</sup> -calmodulin-dependent kinase II
cAMP	Cyclic adenosine monophosphate
CAP	Capsaicin
CAZ	Capsazepine
CD	Cluster of Differentiation
CDK	Cyclin-dependent kinase
CGRP	Calcitonin gene-related peptide
CLL/SLL	Chronic lymphocytic leukaemia/ small lymphocytic lymphoma
CML	Chronic myelogenous leukaemia
CMML	Chronic Myelomonocytic Leukaemia
CNS	Central Nervous System
COPD	Chronic Obstructive pulmonary disease
CRP	C- reactive protein
DAG	Diacylglycerol
DC	Dendritic cell
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DPTHF	Diphenyltetrahydrofuran
DPBA	Diphenylboronic anhydride
DRG	Dorsal root ganglion

ECL	Enhanced Chemiluminescence
eIF2 $\alpha$	Eukaryotic translation initiation factor 2, subunit 1 ( $\alpha$ , 35kDa)
eIF2 $\alpha$ K3	Eukaryotic translation initiation factor-2 $\alpha$ kinase-3
EIPA	Ethylisopropyl amiloride
ER	Endoplasmic reticulum
ET	Essential thrombocythaemia
ETC	Electron transport chain
FBS	Foetal Bovine Serum
FITC	Fluorescein isothiocyanate
FSC	Forward Scatter
GADD153	Growth arrest- and DNA damage-inducible transcript 3
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GARD	Gastroesophageal reflux disease
GM-CSF	Granulocyte-macrophage colony stimulating factor
GTP $\gamma$ S	Guanosine gamma thiophosphate
HCL	Hairy-Cell Leukaemia
HEK293	Human Embryonic Kidney cells
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HL-60	Human myelocytic leukaemia
HRP	Horseradish Peroxidase
ICDA	Inhibitor of caspase activated DNase
IDN	Identification number
IFN- $\gamma$	Interferon-gamma
IL-1/ 2/ 6	Interleukin-1/ 2/ 6
ILD	Interstitial lung disease
Ins(1,4,5)P3	Inositol 1,4,5-trisphosphate
IP <sub>3</sub>	Inositol triphosphate
JNJ17203212	4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide
JYL1421	N-(4-tert-butylbenzyl)-N'-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea
KB-R7943	2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulfonate
LGH	Launceston General Hospital
LNCaP	Androgen-dependent prostate cancer cells
MAPK	Mitogen-activated protein (MAP) kinases
MFI	Median Fluorescence intensity
ML-9	1-(5-chloronaphthalene-1-sulphonyl) homopiperazine
MM	Multiple myeloma
MPD	Myeloproliferative Disorder
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
M.W	Molecular weight
N- terminus	Amino- terminus
NADA	N-arachidonoyldopamine
NADH	Nicotinamide adenine dinucleotide
NFAT	Nuclear factor of activated T-cells

NF- $\kappa$ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
NFM	Non-Fat Milk
NGF	Nerve growth factor
NHBE	Normal human bronchial epithelial
NHL	Non-Hodgkin's Lymphoma
OAG	1-oleoyl-2-acetyl-sn-glycerol
<i>p21</i> <sup>WAF1/CIP1</sup>	Cyclin-dependent kinase inhibitor
PBMC	Peripheral blood mononuclear cell
PBS	Phosphate buffer saline
PBSA	Phosphate buffer saline-sodium azide
PBST	Phosphate buffer saline tween- 20
PC3	Androgen-independent prostate cancer cells
PHB2	Prohibitin
PI3K	Phosphatidylinositol 3-kinase
PIP <sub>2</sub>	Phosphatidyl-inositol-4,5-bisphosphate
PKA	Protein kinases A
PKC	Protein kinases C
PLC	Phospholipase C
PMA	Phorbol 12-myristate 13-acetate
PMT	Photo multiplier tube
PgE <sub>2</sub>	Prostaglandin E <sub>2</sub>
PP	Peyer's patch
PTCL-NOS	Peripheral T-cell lymphoma/ not otherwise specified
PVDF	Polyvinylidene difluoride
Q-PCR	Quantitative real-time PCR
RCF	Relative Centrifugal Force
RHC80267	1,6-di[O-(carbamoyl)cyclohexanone oxime]hexane
ROS	Reactive oxygen species
RT-4	Human well-differentiated low-grade papillary
RT-PCR	Reverse transcription polymerase chain reaction
RTX	Resiniferatoxin
SB366791	N-(3-methoxyphenyl)-4-chlorocinnamide
SDS	Sodium Dodecyl Sulphate
SSC	Side Scatter
STAT	Signal transducer and activator of transcription
TBMC	6-tert-butyl-m-cresol
THC	$\Delta^9$ -tetrahydrocannabinol
TNF- $\alpha$	tumour necrosis factor-alpha
TRAIL	Tumour necrosis factor-related apoptosis-inducing ligand
TRIM	1-(2-(trifluoromethyl)phenyl) imidazole
trkA	Tyrosine kinase A
TRP	Transient receptor potential
TRPV1	Transient receptor potential vanilloid type 1
URB597	3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate.
UTAS	University of Tasmania
V <sub>a</sub>	Varitint-waddler phenotype

WS-12	2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxy-phenyl)-amide
2-APB	2-aminoethoxydiphenyl borate
4 $\alpha$ -PDD	4 $\alpha$ -phorbol 12,13-didecanoate
5-HT	Serotonin
5(6)-EET	5',6'-epoxyeicosatrienoic acid
5-(S)-HETE	5-(S)-hydroxyeicosatetraenoic acid
12-(S)-HPETE and 15-(S)-HPETE	12- and 15-(S)-hydroperoxyeicosatetraenoic acids
20-HETE	20-hydroxyeicosatetraenoic acid
$\Delta\Psi_m$	Mitochondrial membrane potential

## **Presentations at Conferences during PhD Candidature**

### **Conference Presentations**

- **Omari, S** and Adams, MJ and Khalafallah AA and Mohamed, M and Geraghty, DP, TRPV1 expression in haematological malignancies, Annual Combined ASM of APSA and ASCEPT, 1 - 4 December, Melbourne, Australia (2013) [Conference Extract].
- **Omari, S** and Geraghty, DP and Kunde, DA and Adams, MJ, Inhibition of Human Haematological Malignant Cell Lines by Capsaicin is not TRPV1-Mediated, Annual Combined ASM of the HSANZ/ANZBT/ASTH and the APSTH, 28 – 31 October, Melbourne, Australia (2012) [Conference Extract].
- **Omari, S** and Kunde, DA and Adams MJ and Geraghty DP, Inhibition of human haematological malignant cell line growth by capsaicin is not TRPV1-mediated, Annual Combined ASM of APSA and ASCEPT, 2-5 December, Sydney, Australia (2012) [Conference Extract].

### **Presentations related to but not directly arising from this thesis**

#### **Conference Presentation**

- Shegog, YM and **Omari, S** and Adams, MJ and Ragg, S and Eastley, B and Geraghty, DP, Flow cytometric analysis of transient receptor potential vanilloid 1 (TRPV1) in human leukocyte populations, Proceedings of the ASCEPT, December 4- 9, Perth, Australia, pp. p77 (2011) [Conference Extract].

## **Abstract**

Transient receptor potential vanilloid-1 (TRPV1) is a member of the TRP family of channels that are responsible for nociceptive, thermal and mechanical sensations. It is primarily associated with neuronal cells, but has been detected in different non-neuronal cells, including leukocytes. Capsaicin (CAP), the active ingredient of hot chilli peppers, is one of a number of related endogenous and plant-derived compounds (broadly termed ‘vanilloid-like agents’) that have been shown to induce apoptosis and inhibit cell proliferation in some cancer cells, through both TRPV1-dependent and -independent mechanisms. The expression and function of TRPV1 in haematological malignancies however, has not been extensively investigated. Specific targeting by vanilloid-like agents toward TRPV1 on cancerous cells in patients with haematological malignancies may represent a novel therapeutic approach to treating these diseases.

This thesis investigated the expression and function of TRPV1 in haematological malignancies, using both blood cancer cell lines and blood samples obtained from patients with different blood cancers. The specific aims were to; 1) study the effect of TRPV1 agonists and antagonists on the viability of THP-1, U266B1 and U937 haematological malignant cell lines, 2) validate and optimise Western blotting and flow cytometry protocols to detect TRPV1 expression in leukocytes, 3) investigate TRPV1 expression in THP-1, U266B1 and U937 cells, and 4) compare TRPV1 expression in leukocytes obtained from patients with blood cancers to normal subjects.

The thesis begins with a comprehensive review and discussion on TRPV1 structure and function, as well as its expression and role in health and disease. In particular, there is a focus on the role of TRPV1 in cancer, including haematological malignancies (Chapter 1).

In Chapter 2, the effect of CAP on the metabolic activity of three malignant haematological cell lines, THP-1, U266B1 and U937, was investigated. Metabolic activity assays were performed using the alamarBlue<sup>®</sup> method. CAP induced cytotoxicity in all three cell lines in a concentration-dependent manner. A biphasic effect on metabolic activity was observed on THP-1 cells [ $EC_{50}$ ,  $IC_{50}$  (95% CI) = 32.9 (19.9-54.3), 219 (144-246)  $\mu$ M]. U266B1 cells were more resistant to CAP-induced death than THP-1 and U937 cells. TRPV1 and CB1 antagonists (SB452533 and AM251, respectively) suppressed the CAP-induced increase in THP-1 cell metabolic activity ( $P < 0.001$ ). These experiments suggest that CAP inhibits the metabolic activity of malignant haematological cells through a non-TRPV1-dependent mechanism.

Chapters 3 and 4 represent the experimental work and trouble-shooting conducted to develop, validate and optimise methods for the detection of TRPV1 expression in human cells. Western blotting (Chapter 3) and flow cytometric (Chapter 4) methods have been previously published, however few have documented the use of appropriate controls for the detection of TRPV1, suggesting that data in the literature may not necessarily be valid. A problem identified in the current study was the correct application of negative controls, particularly to assess the specificity and therefore suitability of the primary antibody used in these methods. These optimised

protocols were then used to investigate the expression of TRPV1 in human malignant haematological cell lines (Chapter 5) and leukocytes obtained from patients with blood cancers (Chapter 6).

Increased expression of TRPV1 protein was observed in THP-1, U266B1 and U937 cells compared to normal leukocytes. Furthermore, a TRPV1 dimer was detected in U266B1 cells. Interestingly, TRPV1 was detected in non-haematological cell lines that have previously been used as TRPV1-negative cells for Western blotting, including untransfected- and TRPV1-transfected (without tetracycline to switch TRPV1 transcription off) HEK293 and RAW264.7 cells. This latter finding highlights the need for appropriate negative (and positive) controls in both flow cytometric and Western blotting studies of TRPV1.

Expression of TRPV1 in leukocytes obtained from patients with a range of haematological malignancies, including multiple myeloma (MM) and B-cell non-Hodgkin's Lymphoma (B-NHL), was then investigated (Chapter 6). TRPV1 expression was detected in all patients and controls using flow cytometry, but not Western blotting. Using flow cytometry, a sub-group of patients (4/49=8.2%, MM=2, B-NHL=2) demonstrated increased expression of TRPV1 relative to the remainder of the cohort. TRPV1 was found to be similar to the control group for 91.8% of all patients. There were no significant differences in TRPV1 expression (assessed using flow cytometry) between patients with MM and B-NHL, or between *de novo* patients and those undergoing treatment. Using Western blotting, TRPV1 (~95kDa) was detected in one MM and four B-NHL patients, although interestingly, a 240kDa band was also detected in both a B-NHL and a MM patient. In addition,

although C-reactive protein was elevated ( $\geq 5$  mg/L) in 25% of all patients, it was not associated with higher TRPV1 expression. These results indicate that TRPV1 expression in leukocytes is relatively increased in a small subset of patients with blood cancers, and is not associated with inflammation. Furthermore, some patients may have a unique isoform of TRPV1 that warrants further investigation.

In summary, this study has generated new data and knowledge on the role of TRPV1 in haematological cells, including those from patients with blood cancers. A number of novel findings have been reported. Firstly, the inhibition of cell metabolic activity by the TRPV1 agonist, CAP, was found to be independent of TRPV1 activation in malignant haematological cell lines. Secondly, optimised Western blotting and flow cytometric methods for the detection of TRPV1 expression were developed and successfully validated. Thirdly, increased TRPV1 expression was demonstrated in the THP-1, U266B1 and U937 malignant haematological cell lines. Finally, increased TRPV1 expression was observed in some patients with MM and B-NHL, but was not associated with inflammation. The results presented in this thesis can be used as a basis for future studies of TRPV1 function in other human cells and cancers.